These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. Hepp Z; Shah SN; Smoyer K; Vadagam P J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035 [No Abstract] [Full Text] [Related]
3. Immune checkpoint inhibitors for urothelial carcinoma. Kim HS; Seo HK Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073 [TBL] [Abstract][Full Text] [Related]
4. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. Einstein DJ; Sonpavde G Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358 [TBL] [Abstract][Full Text] [Related]
5. The emerging treatment landscape of advanced urothelial carcinoma. Cardenas L; Dibajnia P; Lalani AK Curr Opin Support Palliat Care; 2021 Dec; 15(4):247-252. PubMed ID: 34620772 [TBL] [Abstract][Full Text] [Related]
7. Advances in the management of urothelial carcinoma: is immunotherapy the answer? Santopietro AL; Einstein D; Bellmunt J Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290 [No Abstract] [Full Text] [Related]
8. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Tripathi A; Plimack ER Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502 [TBL] [Abstract][Full Text] [Related]
9. Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts. Santini D; Banna GL; Buti S; Isella L; Stellato M; Roberto M; Iacovelli R Curr Oncol Rep; 2023 Nov; 25(11):1345-1362. PubMed ID: 37855848 [TBL] [Abstract][Full Text] [Related]
10. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. Montazeri K; Sonpavde G Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937 [TBL] [Abstract][Full Text] [Related]
11. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. Tang Q; Li S; Huang G; Liu H Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259 [TBL] [Abstract][Full Text] [Related]
12. Muscle invasive bladder cancer: where is the field headed? Ghatalia P; Kaur J; Sonpavde G Expert Opin Biol Ther; 2023; 23(9):913-927. PubMed ID: 37477127 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446 [TBL] [Abstract][Full Text] [Related]
14. Recent developments in the treatment of advanced bladder cancer. Godwin JL; Hoffman-Censits J; Plimack E Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for the treatment of bladder cancer. Sundahl N; Rottey S; De Maeseneer D; Ost P Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318 [TBL] [Abstract][Full Text] [Related]
19. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Morales-Barrera R; Suárez C; de Castro AM; Racca F; Valverde C; Maldonado X; Bastaros JM; Morote J; Carles J Cancer Treat Rev; 2016 Nov; 50():208-216. PubMed ID: 27743530 [TBL] [Abstract][Full Text] [Related]
20. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy. You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]